MELBOURNE: Genetic Technologies Limited announced the appointment of Simon Morriss to the role of Chief Executive Officer, commencing on 1 February 2021.
Simon brings over 20 years’ experience within the Pharmaceutical, Healthcare and FMCG industries having held senior executive positions at Sanofi and Blackmores.
He brings a wealth of experience in managing teams and successfully executing across sales, marketing and brand building. Additionally, he has been critical in leading commercialisation across these industries and understands the unique pressures and opportunities.
Simon has led companies through strategic adaptation to execution and will be driving Genetic Technologies commercialisation strategy and continue to drive innovation across the business. Additionally, the Board is pleased to announce that George Muchnicki, who has been Acting CEO since September 2019,will be stepping into the role of Chief Medical Officer and Executive Director.
George was critical in advancing both the direction of the Company and the scope of the products in development. In his role as Chief Medical Officer, George will continue to leverage his exceptional background and experience to continue to advance the product development and establish the medical framework for GTGs platform offering.
Commenting on the appointments, Chairman, Peter Rubinstein said, “We are pleased to appoint Simon Morriss to the role of CEO. His extensive experience in commercialising products within the Pharmaceutical and Healthcare industry will be critical for Genetic Technologies as we move from a predominantly research-based business to expanding our commercialisation efforts.”
“We are also pleased to retain the skills and expertise of George in the role of Chief Medical Officer, this will enable a smooth transition as Simon steps into the role of CEO but also critically retains the talent, knowledge and passion to continue to advance our product development and intellectual property.
George has been instrumental in establishing our expanded platform of products and will be critical in continuing to advance the business and petition governments and health care systems on the role genomics should play in preventative health.”
In relation to his appointment as CEO of Genetic Technologies, Mr Morriss said: “I am delighted to be given the opportunity to join Genetic Technologies in the role of CEO. I recognise the exceptional work the management team have done over the last few years and am excited to be joining the Company at such a critical juncture. The growth prospects that exist for Genetic Technologies are substantial given the strong pipeline of products and a large market opportunity.
I look forward to working with the management and board to execute on the strategy and continue to expand GTGs position in preventative health and genomics.”
Simon is a member of the Australian Institute of Company Directors and an Approved Advisor at the Advisory Board Centre.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health.
The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.
Genetic Technologies is developing a pipeline of risk assessment products.
Leave a Reply